Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report

Kai, Yoshiro; Matsuda, Masayuki; Suzuki, Koichi; Kasamatsu, Takehito; Uno, Kenji; Muro, Shigeo

doi:10.7759/cureus.23411

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several medications, such as natural polysaccharides, baicalin, the endocannabinoid system, dihydroartemisinin and (-)-Epigallocatechin-3-gallate, have shown anti-fibrotic effects in preclinical trials but lack clinical trial date[ 23 - 27 ]. Tocilizumab and baricitinib combination therapy has shown effectiveness but has controversial safety concerns[ 21 , 28 ]. PI3K inhibitors hold promise but require further exploration for safe use[ 29 ].…”

Section: Pharmacotherapy Interventionsmentioning

confidence: 99%

Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis

Liu,

Zhang,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

The global spread of severe acute respiratory syndrome coronavirus 2 has resulted in a significant number of individuals developing pulmonary fibrosis (PF), an irreversible lung injury. This condition can manifest within a short interval following the onset of pneumonia symptoms, sometimes even within a few days. While lung transplantation is a potentially lifesaving procedure, its limited availability, high costs, intricate surgeries, and risk of immunological rejection present significant drawbacks. The optimal timing of medication administration for coronavirus disease 2019 (COVID-19)-induced PF remains controversial. Despite this, it is crucial to explore pharmacotherapy interventions, involving early and preventative treatment as well as pharmacotherapy options for advanced-stage PF. Additionally, studies have demonstrated disparities in anti-fibrotic treatment based on race and gender factors. Genetic mutations may also impact therapeutic efficacy. Enhancing research efforts on pharmacotherapy interventions, while considering relevant pharmacological factors and optimizing the timing and dosage of medication administration, will lead to enhanced, personalized, and fair treatment for individuals impacted by COVID-19-related PF. These measures are crucial in lessening the burden of the disease on healthcare systems and improving patients' quality of life.

show abstract